News Releases | Investor Relations - Sangamo Therapeutics, Inc.
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast. Nov 04, 2024. RICHMOND, Calif. -- (BUSINESS WIRE)--Nov. 4, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on ...
Sangamo Therapeutics Announces Evidence of Clinical Benefit in …
Feb 22, 2023 · Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist.
Sangamo Therapeutics Reports Recent Business Highlights and …
May 9, 2024 · RICHMOND, Calif. -- (BUSINESS WIRE)--May 9, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results. “Sangamo continues to progress its neurology-focused genomic medicine pipeline as most recently showcased at the 27 th ASGCT Annual Meeting ...
Investors & Media - Sangamo Therapeutics, Inc.
Dec 12, 2021 · Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist.
PFIZER AND SANGAMO THERAPEUTICS ANNOUNCE PHASE 3 …
New York, NY, and Brisbane, California, September 22, 2022 – Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment.
Sangamo Therapeutics Reports Recent Business Highlights and …
Aug 8, 2023 · Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing ...
Sangamo Announces Global Collaboration With Novartis to …
Jul 30, 2020 · The collaboration will leverage ZFP-TFs engineered by Sangamo scientists in an effort to upregulate, or activate, the expression of genes that are inadequately expressed in individuals with certain types of neurodevelopmental disorders.
Sangamo Therapeutics Announces Third Quarter 2023 Conference …
Oct 25, 2023 · BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 25, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes on Wednesday, November 1, 2023.
Sangamo Therapeutics Reports Recent Business Highlights and …
Aug 4, 2022 · BRISBANE, Calif. -- (BUSINESS WIRE)--Aug. 4, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. “We made meaningful progress advancing our clinical-stage programs in the second quarter,” said Sandy Macrae, Chief Executive Officer ...
Sangamo Therapeutics Announces Dosing of First Patient in Phase …
Mar 29, 2022 · Sangamo expects to dose a second patient in the STEADFAST study in the middle of 2022. The STEADFAST study forms the first step in a pipeline of CAR-Treg programs. In addition to TX200, Sangamo is developing CAR-Treg cell therapy candidates in preclinical studies, including for potential use in treating multiple sclerosis and inflammatory bowel ...